Production (Stage)
X4 Pharmaceuticals, Inc.
XFOR
$3.10
-$0.13-4.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.81M | 1.43M | 560.00K | 563.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.81M | 1.43M | 560.00K | 563.00K | -- |
| Cost of Revenue | 4.72M | 302.00K | 227.00K | 268.00K | -- |
| Gross Profit | 24.09M | 1.13M | 333.00K | 295.00K | -- |
| SG&A Expenses | 15.02M | 15.15M | 15.66M | 13.28M | 17.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.25M | 37.15M | 35.06M | 34.46M | 37.29M |
| Operating Income | -9.44M | -35.72M | -34.50M | -33.90M | -37.29M |
| Income Before Tax | 316.00K | -39.56M | -36.68M | 90.85M | -51.75M |
| Income Tax Expenses | 34.00K | 258.00K | 15.00K | 18.00K | 19.00K |
| Earnings from Continuing Operations | 282.00K | -39.82M | -36.70M | 90.83M | -51.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 282.00K | -39.82M | -36.70M | 90.83M | -51.77M |
| EBIT | -9.44M | -35.72M | -34.50M | -33.90M | -37.29M |
| EBITDA | -8.97M | -35.44M | -34.23M | -33.70M | -37.23M |
| EPS Basic | 0.04 | -5.89 | -5.48 | 13.60 | -7.77 |
| Normalized Basic EPS | 0.03 | -3.66 | -3.42 | -1.32 | -4.85 |
| EPS Diluted | 0.04 | -5.89 | -5.48 | 13.50 | -7.77 |
| Normalized Diluted EPS | 0.03 | -3.66 | -3.42 | -1.32 | -4.85 |
| Average Basic Shares Outstanding | 6.84M | 6.76M | 6.70M | 6.68M | 6.67M |
| Average Diluted Shares Outstanding | 6.87M | 6.76M | 6.70M | 6.69M | 6.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |